Methods and kits for predicting the responsiveness of hepatocellular carcinoma patients to 5-fluorouracil-based combination chemotherapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8709720
APP PUB NO 20130230847A1
SERIAL NO

13411306

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein is a method for identifying single nucleotide polymorphisms of a target nucleic acid for predicting whether a patient suffering from hepatocellular carcinoma will respond to a 5-fluorouracil (5-FU)-based combination chemotherapy. In some embodiments, biological sample derived from the patient is processed to determine the presence of a T/T genotype of rs9679162 GALNT14 gene. The presence of the above-identified genotype is an indication that the patient is responsive to the 5-FU-based combination chemotherapy.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • CHANG GUNG MEMORIAL HOSPITAL, LINKOU;CHANG GUNG UNIVERSITY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Liang, Kung-Hao Gueishan Township, Taoyuan County, TW 7 10
Yeh, Chau-Ting Gueishan Township, Taoyuan County, TW 13 11

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 29, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00